Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC
Clinical trial NCT07377916 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07377916
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-15
- Primary completion
- 2029-06-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.